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PATH, an international nonprofit organization, assessed nearly 40 technologies for their potential to reduce
maternal mortality from postpartum hemorrhage and preeclampsia and eclampsia in low-resource settings. The
evaluation used a new Excel-based prioritization tool covering 22 criteria developed by PATH, the Maternal and
Neonatal Directed Assessment of Technology (MANDATE) model, and consultations with experts. It identified five
innovations with especially high potential: technologies to improve use of oxytocin, a uterine balloon tamponade,
simplified dosing of magnesium sulfate, an improved proteinuria test, and better blood pressure measurement
devices. Investments are needed to realize the potential of these technologies to reduce mortality.
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Innovations in health technologies and services are often
least available to people with the greatest health needs
[1,2]. Because many women in low-resource settings lack
access to basic maternal health technologies and ser-
vices, more than 30 women die each hour from compli-
cations related to pregnancy and childbirth, mostly in
sub-Saharan Africa and South Asia [3,4].
Many factors make it difficult to get needed maternal
health innovations to women in low-resource settings
[1]. These include serious health system deficiencies,
such as the limited capacity of health staff. They also in-
clude technology-focused challenges, such as:
 Complicated user requirements for technologies,
especially for health workers without advanced
training.
 Weak or nonexistent distribution systems.
 Disparate markets and small sales volumes
that drive up costs for manufacturing and
distribution.
 Expensive clinical studies.
 Restrictive policy and regulatory guidelines.* Correspondence: therrick@path.org
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reproduction in any medium, provided the orTargeted investment and collaboration to address these
challenges may help to bring lifesaving technologies to all
women rather than just those in the richest countries.
Millennium Development Goal 5 aims to reduce the
maternal mortality ratio by 75 percent by 2015 [3,4]. To
accelerate progress toward this goal, Merck & Co., Inc.,
launched Merck for Mothers, a ten-year initiative to re-
duce maternal mortality.
In October 2011, PATH received funding through
Merck for Mothers to identify the most promising tech-
nologies with the potential to help save women’s lives.
PATH is an international nonprofit organization with
nearly four decades of experience adapting, develop-
ing, and introducing health technologies for developing
countries.
Methods
PATH identified 38 technologies for evaluation, with
emphasis on those that address postpartum hemorrhage
and preeclampsia and eclampsia, the leading causes of
maternal death. We identified these technologies by re-
viewing World Health Organization (WHO) guidelines,
Bill & Melinda Gates Foundation Grand Challenges in
Global Health awards, and US Agency for International
Development Saving Lives at Birth finalists, as well as by
soliciting input from maternal health experts and other
stakeholders.Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the technologies and then create strategies to advance
those with the greatest promise. The goal of phase 1 was
to identify the 10 best technology opportunities for add-
itional analysis. To winnow the list, PATH needed a way
to assess all the criteria that affect a technology’s poten-
tial impact.
Because our review of the literature found that no
existing assessment tool would meet our needs, PATH
developed a strategic prioritization tool for the project
[see Additional file 1]. The tool is a decision matrix con-
sisting of 22 criteria, each representing a discrete elem-
ent of the technology’s value proposition and potential
for impact (see Table 1). The matrix captures a score for
each criterion, a cumulative score, and score substanti-
ation for each technology. To develop the criteria and
related definitions, project staff consulted internal ma-
ternal health experts, commercial firms, and other sour-
ces [5]. The tool and detailed information on the criteria,
definitions, and process are available online at http://sites.
path.org/mnhtech/assessment/tool/. (If the Uniform Re-
source Locator [URL], or web address, for a site men-
tioned in this manuscript changes, the authors will inform
readers by adding a comment to the manuscript online).
The tool encompasses five categories of criteria that
influence potential impact:
 The gap-filling potential for health. This category
focuses on the technology’s potential for reducing
morbidity and mortality and filling existing “gaps.”
Technologies that are used earlier in the treatment
continuum (e.g., prevention) generally receive a
higher ranking because of their potential to prevent
life-threatening conditions, reduce unnecessary
morbidity and mortality, and reduce the need for
emergency care. Other considerations in this
category include the strength of available data and
the percentage of cases that could be better
managed with the technology.
 Technology performance. The criteria in this
category concern the clinical performance, safety,
and ease of use of the technology compared to an
existing benchmark, which we identified by
reviewing WHO guidelines. We also evaluated usage
requirements to highlight factors that may influence
appropriate use in low-resource settings. These
requirements include fragile handling, shelf life,
waste disposal, specialized storage needs, electrical
power requirements, infection prevention, and
training.
 Enabling factors. We use this category to determine
whether an enabling environment is in place for
successful technology introduction. Factors include
alignment with international guidelines, existingsupport, an acceptability profile, and existing
capabilities.
 Market considerations. We use the criteria in this
category to evaluate the time and investment needed
to bring a technology to market as well as the health
care setting and type of health worker most likely to
use the technology.
 Unique considerations. With this category, we assess
other factors that may significantly affect the
introduction and scaling of the technology, such as
system and bundling requirements and potential
disruption of existing systems. “Disruption” is
defined as any significant shift in costs, roles, or
risks of any of the stakeholders that are involved in
the acquisition, distribution, or deployment of
technologies.
In phase 2 of the assessment, PATH applied different
methods to further narrow the focus to a handful of
technologies with the greatest promise. For example,
PATH used the Maternal and Neonatal Directed Assess-
ment of Technology (MANDATE) model developed by
Research Triangle Institute to assess the potential num-
ber of lives saved for each technology (for more infor-
mation, see http://mnhtech.org). We also conducted an
online survey with maternal health experts to rank can-
didate technologies for their potential to reduce morta-
lity in sub-Saharan African and South Asia. The survey
was sent to 63 maternal health experts with developing-
country expertise from a variety of organizations and
was completed by 34 individuals (54% response rate) in
April 2012.
Results and discussion
Our systematic evaluation identified five types of tech-
nologies with especially high potential for reducing deaths
from postpartum hemorrhage and preeclampsia and ec-
lampsia in low-resource settings:
 Technologies to facilitate appropriate use of oxytocin.
Although WHO recommends oxytocin for
preventing and managing postpartum hemorrhage,
this drug is unavailable to many women, as
highlighted in a recent report from the United
Nations Commission on Life-Saving Commodities
for Women and Children [6]. Expanding its use will
likely require developing and introducing easy-to-
use formats appropriate for low-resource settings.
Developing heat-stable formulations, for example,
may eliminate or reduce the need for cold chain
storage and enable broader use, especially for home
births [7]. Also, formulations for alternative methods
of administration (e.g., via inhalation or sublingual
delivery) may increase safety and allow even
Table 1 Assessment criteria for technologies that address postpartum hemorrhage and preeclampsia and eclampsia
Category Criteria Evaluation approach (high, medium, low)*
Gap Gap-filling potential for health Evaluate what layers of the treatment continuum could
most greatly reduce mortality (e.g., prevention, diagnostics,
treatment), the strength of the available data, and the
percentage of cases that could be managed
Technology performance Clinical evidence (efficacy/effectiveness) Superior to benchmark,** similar to benchmark, inferior to
benchmark
Safety (patient/health care worker) Superior to benchmark,** similar to benchmark, inferior to
benchmark
Ease of use Superior to benchmark,** similar to benchmark, inferior to
benchmark
Usage requirements (e.g., durability, shelf life, electricity,
storage temperature)
Technology has two or fewer usage requirements,
technology has between three and five usage
requirements, technology has greater than five usage
requirements
Enabling factors Alignment with internationally recognized guidelines (e.g.,
the World Health Organization, the International Federation
of Gynecology and Obstetrics, and the International
Confederation of Midwives)
Technology is recommended by at least one organization,
divergent opinions exist, technology is not recommended
Donor financial support (product development or
implementation)
Funding greater than US$5 M, between US$1 M and US
$5 M, less than US$1 M (or no funding identified)
Other nonfinancial support Placeholder for other nonfinancial supporters that may not
be captured elsewhere; not scored
Acceptability profile Broadly acceptable, mixed, acceptable in few geographies
(South Asia and sub-Saharan Africa)
Organizational capabilities All key partners have experience with the technology, a
subset of key partners has experience with the technology,
none of the key partners has experience with the
technology
Market analysis Manufacturing costs Superior to benchmark** (lower cost), similar to benchmark,
inferior to benchmark (higher cost)
Distribution system requirements (warehouse, cold chain,
transportation factors)
Infrastructure for a distribution channel(s) exists and high
likelihood of utilization, infrastructure for distribution
channel(s) exists and moderate likelihood of utilization,
distribution channel(s) does not exist or a low likelihood of
utilization
Manufacturing plan established Capture manufacturing information including delays,
hurdles, risk, and complexity; not scored
Target setting (community, primary health care, hospital) Capture setting(s) where the technology would be used;
not scored
Target provider/administrator Community health care worker, nurse or midwife, physician
Potential multiple markets (additional value to the health
care system)
Additional uses identified (high), no additional uses (low)
Technology readiness level (clinical/regulatory development) Regulatory or commercialization, confirmatory, discovery, or
exploratory
Cost of clinical development Less than US$5 M, between US$5 M and US$50 M, greater
than US$50 M
Clarity of regulatory/clinical pathways Class I US Food and Drug Administration (USFDA) device,
class II USFDA device, class III USFDA device or requires
efficacy data (e.g., drugs)
Unique considerations System requirements (disruption) Low system requirements (training/infrastructure), modest
system requirements, high system requirements
Product bundling No other technologies required for impact, likely need to
bundle with one technology, likely need to bundle with
two or more technologies
Other Placeholder for other unique considerations; not scored
*Detailed definitions are available at http://sites.path.org/mnhtech/assessment/tool/.
**Benchmark based on WHO treatment guidelines or the best benchmark for that technology category.
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There is a need for accelerated investment in
new heat-stable formulations and alternative
administration methods.
 Uterine balloon tamponade. This elastomeric
bladder-like device can be inserted into the uterus
and filled with saline to control severe postpartum
bleeding [8]. It works rapidly and effectively,
reducing the need for risky surgical interventions
and blood transfusions [9,10]. Commercially
available models, however, are too expensive for
widespread use in developing countries, and
performance of some versions is inconsistent.
Investments are needed to gather clinical evidence
for efficacy in low-resource settings through
randomized, controlled trials of new, affordable
devices under development.
 Simplified dosing of magnesium sulfate. WHO has
identified magnesium sulfate as the most effective,
safe, and low-cost medication for preventing and
treating convulsions for women with severe
preeclampsia or eclampsia [11]. Recommended
dosing, however, requires a complicated
combination of intravenous and intramuscular
injection, and health workers in peripheral facilities
may be unable to provide this treatment. Simplified
dosing and dose packaging are feasible and could help
providers more easily give women the medicine they
need [12]. There is an immediate need for a
randomized, controlled trial to determine whether a
simplified, single, loading-dose-only regimen can
effectively prevent and treat preeclampsia and
eclampsia.
 Improved proteinuria test. Although detection of
proteinuria is critical for diagnosing preeclampsia,
most women in developing countries are not tested
for proteinuria because tests are either unavailable
or simply not used, and existing technologies have
poor performance [13]. Investments are needed to
assess novel, easy-to-use methods of proteinuria
detection in the laboratory and then develop
advanced prototypes for evaluation in low-
resource settings.
 Blood pressure measurement devices. Like testing
for proteinuria, measurement of blood pressure is
critical for diagnosing preeclampsia. Health care
providers in low-resource settings often fail to
detect hypertension because suitable measurement
devices are not available or they do not have
needed skills [14]. There is a need for low-cost
blood pressure measurement devices that are
validated for use with pregnant women and
that conform to WHO recommendations and
international standards.In phase 3 of the project, PATH created strategies to
advance select technologies for introduction, scale-up,
and ultimately impact.
Conclusion
Further development and introduction of maternal health
technologies designed for use in low-resource settings will
help to save many women’s lives. Through a systematic as-
sessment, PATH has identified five technologies with high
potential for impact and provided a basis for prioritizing
investments. Especially in times of significant resource
constraints, it is critical for donors, national governments,
businesses, and other stakeholders to determine the best
use of scarce resources to improve maternal health. In-
vesting in high-impact technologies and services and col-
laborating to advance their use will build brighter futures
for women, families, communities, and nations.
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